Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

Garibs Apr. 17 at 3:42 PM

$JNJ is this a short?

0 · Reply

johngold Apr. 17 at 3:06 PM

$JNJ https://seekingalpha.com/article/4891588-johnson-and-johnson-why-i-see-downside-ahead WTH

0 · Reply

trenddetector Apr. 17 at 2:17 PM

$GSK $LLY $MRK $JNJ Too many updates to list. Explore every approved cancer treatment, every open clinical trial, and every option your doctor might not know to mention. yourcancerpath.com/

0 · Reply

DragonAlgo Apr. 17 at 2:04 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-17 | Strike: $250.00 | Type: CALL Option Plan (premium): Entry: $0.04 Stop: $0.03 TP1: $0.05 TP2: $0.07 TP3: $0.10 🔗 https://dragonalgo.com

0 · Reply

maikl_211 Apr. 17 at 12:55 PM

$JNJ $ASML $MA $NVDA $PLTR

0 · Reply

Arcides Apr. 17 at 12:29 AM

$JNJ will it breakdown? loooks like an inverted base.

0 · Reply

trenddetector Apr. 16 at 7:27 PM

$CYDY $GSK $MRK $JNJ Too many updates to list. Explore every approved treatment, every open clinical trial, and every option your doctor might not know to mention. www.yourcancerpath.com/

0 · Reply

Bazzzigar Apr. 16 at 6:52 PM

$JNJ few more

0 · Reply

Bazzzigar Apr. 16 at 6:19 PM

$JNJ CVS

0 · Reply

lextrading Apr. 16 at 5:52 PM

$JNJ Topped out since February.

0 · Reply

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

LLY MGTX

Apr 15, 2026, 4:11 PM EDT - 1 day ago

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Apr 15, 2026, 1:43 PM EDT - 1 day ago

These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results

Apr 15, 2026, 12:37 PM EDT - 1 day ago

Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst

Apr 14, 2026, 10:51 AM EDT - 3 days ago

Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:30 AM EDT - 3 days ago

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

ORCL BE KMX

Apr 14, 2026, 6:55 AM EDT - 3 days ago

J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:25 AM EDT - 3 days ago

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Apr 14, 2026, 6:21 AM EDT - 3 days ago

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Apr 14, 2026, 6:20 AM EDT - 3 days ago

J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Apr 14, 2026, 6:20 AM EDT - 3 days ago

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Apr 13, 2026, 11:36 AM EDT - 4 days ago

Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports

JPM DIA TRV

Apr 12, 2026, 2:00 PM EDT - 4 days ago

Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week

NFLX BAC GS JPM

Apr 10, 2026, 8:00 AM EDT - 7 days ago

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Apr 9, 2026, 7:57 AM EDT - 8 days ago

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Apr 8, 2026, 10:41 AM EDT - 9 days ago

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Apr 7, 2026, 8:00 AM EDT - 10 days ago

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Mar 30, 2026, 9:14 AM EDT - 18 days ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

Mar 28, 2026, 10:00 AM EDT - 20 days ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 27, 2026, 4:46 PM EDT - 20 days ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 6:31 AM EDT - 21 days ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 19, 2026, 1:00 PM EDT - 4 weeks ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

Mar 19, 2026, 9:35 AM EDT - 4 weeks ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 18, 2026, 2:23 PM EDT - 4 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

Mar 18, 2026, 1:17 PM EDT - 4 weeks ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 8:31 AM EDT - 4 weeks ago

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 7:49 AM EDT - 4 weeks ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 16, 2026, 11:00 AM EDT - 4 weeks ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 13, 2026, 12:35 PM EDT - 4 weeks ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 12, 2026, 8:00 AM EDT - 5 weeks ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

$Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line$

Mar 5, 2026, 3:55 PM EST - 6 weeks ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 2:21 PM EST - 6 weeks ago

US FDA approves JNJ's blood cancer drug

Mar 4, 2026, 6:07 PM EST - 6 weeks ago

Johnson & Johnson launches website for direct-to-consumer sales

Mar 3, 2026, 8:03 AM EST - 6 weeks ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 2, 2026, 4:30 PM EST - 6 weeks ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Feb 26, 2026, 2:30 PM EST - 7 weeks ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 24, 2026, 4:03 PM EST - 7 weeks ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 23, 2026, 11:35 AM EST - 7 weeks ago

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 10:43 AM EST - 7 weeks ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:28 AM EST - 7 weeks ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 21, 2026, 8:00 AM EST - 7 weeks ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 19, 2026, 5:00 PM EST - 2 months ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 2:34 PM EST - 2 months ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:11 PM EST - 2 months ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 18, 2026, 10:44 AM EST - 2 months ago

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:17 AM EST - 2 months ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:15 AM EST - 2 months ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 7:30 AM EST - 2 months ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 17, 2026, 8:00 AM EST - 2 months ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 13, 2026, 4:19 PM EST - 2 months ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Garibs Apr. 17 at 3:42 PM

$JNJ is this a short?

0 · Reply

johngold Apr. 17 at 3:06 PM

$JNJ https://seekingalpha.com/article/4891588-johnson-and-johnson-why-i-see-downside-ahead WTH

0 · Reply

trenddetector Apr. 17 at 2:17 PM

$GSK $LLY $MRK $JNJ Too many updates to list. Explore every approved cancer treatment, every open clinical trial, and every option your doctor might not know to mention. yourcancerpath.com/

0 · Reply

DragonAlgo Apr. 17 at 2:04 PM

0 · Reply

maikl_211 Apr. 17 at 12:55 PM

$JNJ $ASML $MA $NVDA $PLTR

0 · Reply

Arcides Apr. 17 at 12:29 AM

$JNJ will it breakdown? loooks like an inverted base.

0 · Reply

trenddetector Apr. 16 at 7:27 PM

$CYDY $GSK $MRK $JNJ Too many updates to list. Explore every approved treatment, every open clinical trial, and every option your doctor might not know to mention. www.yourcancerpath.com/

0 · Reply

Bazzzigar Apr. 16 at 6:52 PM

$JNJ few more

0 · Reply

Bazzzigar Apr. 16 at 6:19 PM

$JNJ CVS

0 · Reply

lextrading Apr. 16 at 5:52 PM

$JNJ Topped out since February.

0 · Reply

hyenacorp Apr. 16 at 5:31 PM

$JNJ

0 · Reply

DragonAlgo Apr. 16 at 5:27 PM

🐉 $JNJ PUT — DragonAlgo® Signal Contract: JNJ PUT Expiry: 2026-04-24 | Strike: $235.00 | Type: PUT Option Plan (premium): Entry: $4.12 Stop: $2.97 TP1: $5.36 TP2: $7.01 TP3: $9.90 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

racernic Apr. 16 at 5:02 PM

$JNJ needs to recover this line here. i am short btw

1 · Reply

Abouelyazeed Apr. 16 at 4:58 PM

$BFRG Trump signals U.S. support for psychedelic PTSD treatments—igniting a new wave of biotech and AI-driven drug discovery plays like BFRG. $LLY $PFE $JNJ $NVS

0 · Reply

Suite510 Apr. 16 at 1:56 PM

$JNJ lol what up? or down 🤣🥃💵

0 · Reply

yellowstar16 Apr. 16 at 1:50 PM

$JNJ https://stocks.apple.com/ABfJBCq8XT5-i-3kyaLbXIQ

0 · Reply

ODucks Apr. 16 at 11:16 AM

$JNJ Timeless. Will only continue to go up. Do your DD before you invest.

0 · Reply

StockMacroView Apr. 16 at 10:24 AM

Johnson & Johnson ($JNJ) has officially announced a 3.1% increase in its quarterly dividend. This hike underscores the healthcare giant’s robust cash flow and its steadfast commitment to shareholder returns. As a long-standing Dividend King, JNJ continues to demonstrate its defensive strength and financial resilience in a shifting market. 👉Click to view @StockMacroView for timely updates amid the volatility.

0 · Reply

hyenacorp Apr. 16 at 7:06 AM

$JNJ

0 · Reply

DragonAlgo Apr. 15 at 10:05 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-17 | Strike: $240.00 | Type: CALL Option Plan (premium): Entry: $1.21 Stop: $0.87 TP1: $1.57 TP2: $2.05 TP3: $2.89 🔗 https://dragonalgo.com

0 · Reply

frb1985 Apr. 15 at 9:39 PM

$JNJ a lot great new highs. LOL

0 · Reply

focafoca99 Apr. 15 at 9:13 PM

$JNJ to participate in the Bank of America 2026 Healthcare Conference https://www.rapidticker.com/news/jnj-johnson-amp-johnson-to-participate-66bd83

0 · Reply

Market Cap	574.86B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	22.38
Forward PE	20.83
Profit Margin	28.46%
Debt to Equity Ratio	0.48

Volume	8,668,800
Avg Vol	8,269,224
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	20%
Beta	0.34
Analysts	Strong Sell
Price Target	$243.96